Farheen Shaikh Selected Research

saroglitazar

1/2022	Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.
1/2022	Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial.
1/2021	A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Farheen Shaikh Research Topics

Disease

2	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 01/2022 - 01/2021
1	Hypertriglyceridemia 01/2022
1	Dyslipidemias (Dyslipidemia) 01/2022
1	Obesity 08/2021
1	Diabetic Nephropathies (Diabetic Nephropathy) 05/2020
1	Diabetes Mellitus 05/2020

Drug/Important Bio-Agent (IBA)

3	saroglitazarIBA 01/2022 - 01/2021
2	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 01/2022 - 01/2021
1	Fibric Acids (Fibrates)IBA 01/2022
1	Alkaline PhosphataseIBA 01/2022
1	Fenofibrate (CiL)FDA LinkGeneric 01/2022
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 08/2021
1	Thiamine (Aneurin)FDA Link 05/2020
1	Therapeutic UsesIBA 05/2020

Therapy/Procedure

1	Therapeutics 05/2020